Entegris Q2 2026: Sales Surge 11.5% to $883M, EPS Beats as Margins Expand and Debt Falls
ENTG has more than doubled off its 52-week low of $67.97.
Summary
Entegris reported Q2 2026 sales of $883.2M (+11.5% YoY) and non-GAAP EPS of $0.93, beating expectations. Gross margins expanded to 47.6%, and the company reduced debt by $200M while upsizing its credit facility.
Key Events · Earnings and Guidance · ENTG
-
Q2 Sales Beat
Net sales rose 11.5% YoY to $883.2M, exceeding the company's own guidance and the $835M consensus, driven by broad-based semiconductor demand.
-
Margin Expansion
Gross margin expanded 320 bps to 47.6%, and operating margin reached 18.6%, aided by higher volumes and a $18.7M reduction in depreciation from an accounting change.
-
Debt Reduction & Facility Upsize
Repaid $200M of term loans in Q2, bringing total debt to $3.495B. Also amended the revolving credit facility to $750M and extended maturity to 2031.
-
Restructuring & Impairment
Incurred $5.6M in restructuring charges, primarily from winding down the Life Sciences Fluid Management business, and a $6.7M equity investment impairment.
Analysis · ENTG · Industrial Applications And Services
A standout quarter for Entegris underscores the semiconductor recovery, with sales climbing 11.5% to $883 million—comfortably ahead of both internal guidance and consensus. Gross margin widened 320 basis points to 47.6%, fueled by higher volumes and a favorable change in asset useful lives that trimmed depreciation. Operating income surged 55%. The balance sheet also strengthened: the company repaid $200 million of term loans and upsized its revolving facility. While restructuring charges tied to a non-core business wind-down and an equity impairment created modest headwinds, the underlying operational momentum is unmistakable. The results highlight Entegris's ability to translate revenue growth into expanding profitability.
At the time of this filing, ENTG was trading at $143.94 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $22B. The 52-week trading range was $67.97 to $186.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.